Novavax, Inc.  

(Public, NASDAQ:NVAX)   Watch this stock  
Find more results for NVAX
8.58
-0.07 (-0.81%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.40 - 8.81
52 week 3.70 - 9.95
Open 8.65
Vol / Avg. 2.41M/4.55M
Mkt cap 2.30B
P/E     -
Div/yield     -
EPS -0.36
Shares 267.85M
Beta 1.28
Inst. own 62%
May 7, 2015
Q1 2015 Novavax Inc Earnings Call - 4:30PM EDT - Add to calendar
May 7, 2015
Q1 2015 Novavax Inc Earnings Release - 4:00PM EDT - Add to calendar
Apr 15, 2015
Novavax Inc at Needham Healthcare Conference
Feb 26, 2015
Q4 2014 Novavax Inc Earnings Call
Feb 26, 2015
Q4 2014 Novavax Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -469.16% -270.55%
Operating margin -470.93% -272.97%
EBITD margin - -255.03%
Return on average assets -44.51% -32.46%
Return on average equity -51.51% -38.33%
Employees 308 -
CDP Score - -

Address

20 Firstfield Rd
GAITHERSBURG, MD 20878-1760
United States - Map
+1-240-2682000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company focusing on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. The Company's product pipeline focuses on a variety of infectious diseases and the Company's vaccine candidates have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus (RSV). The Company�s joint venture, Cadila Pharmaceuticals Limited (CPL) Biologics Private Limited, develops a rabies vaccine candidate that is genetically engineered by Novavax. CPL Biologics Private Limited completed initial pre-clinical immunogenicity studies on this new vaccine candidate and is progressing with pre-clinical toxicology studies.

Officers and directors

James F. Young Ph.D. Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Stanley C. Erck President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Barclay A. Phillips Chief Financial Officer, Senior Vice President, Treasurer
Age: 51
Bio & Compensation  - Reuters
Gregory M. Glenn M.D. Senior Vice President - Research & Development
Age: 60
Bio & Compensation  - Reuters
Sven Andreasson Senior Vice President - Corporate Development
Age: 63
Bio & Compensation  - Reuters
Timothy J. Hahn Ph.D. Senior Vice President - Manufacturing and Process Development
Age: 50
Bio & Compensation  - Reuters
Cynthia N. Oliver Ph.D. Senior Vice President - Process Development Operations
Bio & Compensation  - Reuters
John J. Trizzino Senior Vice President - Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Russell P. Wilson J.D. Senior Vice President - Business Development
Age: 54
Bio & Compensation  - Reuters
Louis F. Fries Vice President, Chief Medical Officer
Bio & Compensation  - Reuters